Novel Drug Imetelstat Shows Transfusion Independence in MDS Novel Drug Imetelstat Shows Transfusion Independence in MDS

The novel telomerase inhibitor allowed patients with lower-risk myelodyplastic syndrome (MDS) who were heavily dependent on transfusions to become transfusion independent for a median of 20 months.Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news